OncoMatch/Clinical Trials/NCT06404840

Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

Is NCT06404840 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including nimotuzumab and AG chemotherapy for pancreatic cancer.

Phase 2RecruitingTianjin Medical University Cancer Institute and HospitalNCT06404840Data as of May 2026

Treatment: nimotuzumab · AG chemotherapy — Patients with PCLM account for the majority of our department's pancreatic cancer cases and often have limited surgical options due to the aggressive nature of their tumors. For those with good performance status (ECOG PS 0-1), NCCN recommends gemcitabine + nab-paclitaxel (AG). Though nimotuzumab combined with gemcitabine improves survival, there remains scarce clinical data regarding its efficacy in conjunction with AG for treating PCLM. This study aims to evaluate the safety and efficacy of incorporating nimotuzumab with AG for PCLM.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Disease stage

Metastatic disease required

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: antitumor chemotherapy

Exception: adjuvant chemotherapy completed at least 6 months prior

Antitumor chemotherapy and molecular targeted therapy as a palliative measure

Cannot have received: molecular targeted therapy

Exception: adjuvant chemotherapy completed at least 6 months prior

Antitumor chemotherapy and molecular targeted therapy as a palliative measure

Cannot have received: radiotherapy

Exception: if target lesion has not progressed

The target lesion has undergone radiotherapy without any progression

Cannot have received: major surgery

Received major surgery within 4 weeks

Lab requirements

Blood counts

Absolute count of granulocytes 1.5 d7 10^9/L; Platelets 100 d7 10^9/L; Hemoglobin 90 g/L

Kidney function

Creatinine clearance rate 60ml/min

Liver function

Serum AST/ALT 5 times ULN; Total bilirubin 3 times ULN

Serum AST/ALT 5 times ULN; Total bilirubin 3 times ULN; Absolute count of granulocytes 1.5 d7 10^9/L; Platelets 100 d7 10^9/L; Hemoglobin 90 g/L; Creatinine clearance rate 60ml/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify